About: Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article by Hermann Haller et al published 10 March 2011 in The New England Journal of Medicine

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в березні 2011 (uk) article scientifique publié en 2011 (fr) im März 2011 veröffentlichter wissenschaftlicher Artikel (de) article by Hermann Haller et al published 10 March 2011 in The New England Journal of Medicine (en)
publication date	wds:Q57605349-36BFD39D-CF23-47B0-80BC-4453BBCA951F
publication date	2011-03-10 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q57605349-77D19646-8F5B-42AC-BDE7-A8B8B6764D59
language of work or name	English
author name string	wds:Q57605349-09BA7FED-FC9F-4F9B-B33A-A1BBBD8A6C96 wds:Q57605349-2BC1197C-9EE3-4A2F-A337-8AC1C6D1FA98 wds:Q57605349-7F4C0E09-3357-4F42-91C4-958B4F71358D wds:Q57605349-8AF8F65B-99D7-48FC-BF81-14E043FBD1A9 wds:Q57605349-C1D78C6C-3B3E-4CA2-B4A9-01B709B07C48 wds:Q57605349-CCA5A96D-D498-4EF4-940A-D6777E7B0B03 wds:Q57605349-D77AC0DD-9662-4DF4-AFFC-103F4DBCE926 wds:Q57605349-F821AB93-9247-4CD4-A874-4950DD004A54
author name string	Giancarlo Viberti Eberhard Ritz Albert Mimran Shigehiro Katayama Jan Menne Ton J. Rabelink Joseph L. Izzo Lars C. Rump
rdfs:label	Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes (en) Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes (nl)
skos:prefLabel	Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes (en) Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes (nl)
name	Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes (en) Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes (nl)
author	wds:Q57605349-0735F6EB-6937-435F-A535-A782E76EDD03 wds:Q57605349-580DDA83-92C4-42EF-B47A-EA86AD458496 wds:Q57605349-9BDC09B8-F15A-4A40-8394-5268BEF55FEC wds:Q57605349-A8FA1586-00A7-4D14-A7B6-4960A75B218D wds:Q57605349-F2D51581-3C8A-4F27-BACC-A61336D018B5
author	Sadayoshi Itō Hermann Haller Krzysztof Narkiewicz Luis Miguel Ruilope Andrzej Januszewicz
title	wds:Q57605349-3C524E20-BB0A-4B0C-9B84-7BFE2A8C1896
title	Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes (en)
page(s)	wds:Q57605349-04DF4F0E-D91F-4296-BA00-B46414BA3AD6
page(s)	907-917
instance of	wds:Q57605349-0685540C-2A18-4E11-9DEC-598DB21B98A6
instance of	scholarly article
main subject	wds:Q57605349-4FCE31D2-A16D-48BB-AA2E-00E20ECBD70A
main subject	type 2 diabetes
PubMed ID	wds:Q57605349-E7C4836B-4378-4638-96E4-7DB830D5DD89
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/21388309
PubMed ID	21388309
published in	wds:Q57605349-F9398209-2F36-4F73-9B65-A381AA6F295D
published in	The New England Journal of Medicine
issue	wds:Q57605349-AE747F80-737D-48D3-8570-D941B8267ACF
volume	wds:Q57605349-0F9C622D-8B6D-4C66-9A6B-B0AF5B13834F
issue	10
volume	364
DOI	wds:Q57605349-C18E6AC0-1A26-46C7-9FE7-99C5EAE522BC
DOI	http://dx.doi.org/10.1056/NEJMOA1007994
DOI	10.1056/NEJMOA1007994
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57605349
is cites work of	Temporal trends in the prevalence of diabetic kidney disease in the United States Disparities in blood pressure control within a community-based provider network: an exploratory analysis Implementation of proteomic biomarkers: making it work The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Redefining blood pressure targets in high-risk patients?: lessons from coronary endpoints in recent randomized clinical trials The kidney in type 2 diabetes therapy Present and future in the treatment of diabetic kidney disease Urinary angiotensinogen as a novel early biomarker of intrarenal renin-angiotensin system activation in experimental type 1 diabetes Urinary proteomics for early diagnosis in diabetic nephropathy Biomarkers in diabetic nephropathy: Present and future Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study. Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes Standards of medical care in diabetes--2013 Standards of medical care in diabetes--2012 Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses The past, present and future of renin-angiotensin aldosterone system inhibition Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy GWAS of diabetic nephropathy: is the GENIE out of the bottle? Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation Cardiovascular and mortality risk in elderly Medicare beneficiaries treated with olmesartan versus other angiotensin receptor blockers. Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats Current and Future Treatment of Hypertension in the SPRINT Era Proximal tubular angiotensinogen in renal biopsy suggests nondipper BP rhythm accompanied by enhanced tubular sodium reabsorption Study design of DIACORE (DIAbetes COhoRtE) - a cohort study of patients with diabetes mellitus type 2. Proteinuria and its relation to cardiovascular disease Cardinal role of the intrarenal renin-angiotensin system in the pathogenesis of diabetic nephropathy Controversies in blood pressure goal guidelines and masked hypertension The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review Olmesartan-associated enteropathy: results of a national survey. The Different Therapeutic Choices with ARBs. Which One to Give? When? Why? ROADMAP and ORIENTAL Trials: the Re-emergence of J-Curve Ghost? Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software